Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Cognition Therapeutics Inc (CGTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cognition Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.010 +0.090    +4.69%
01:20:09 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 78,949
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.900 - 2.015
Cognition Therapeutics 2.010 +0.090 +4.69%

Cognition Therapeutics Inc Company Profile

 
Get an in-depth profile of Cognition Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

27

Equity Type

ORD

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Contact Information

Address 2500 Westchester Ave.
Purchase, 10577
United States
Phone 412 481 2210
Fax -

Top Executives

Name Age Since Title
Susan Catalano 59 2007 Member of Scientific Advisory Board
John Cirrito - - Member of Scientific Advisory Board
Michael Grundman - 2022 Member of Medical Advisory Board
Cynthia A. Lemere - - Member of Scientific Advisory Board
Harry LeVine - - Member of Scientific Advisory Board
Alison M. Goate - - Member of Scientific Advisory Board
Steven T. DeKosky - - Member of Medical Advisory Board
Jack A. Khattar 63 2020 Independent Chairman of the Board
Robert H. Mach - - Member of Scientific Advisory Board
Tara L. Spires-Jones - - Member of Scientific Advisory Board
Aaron Glenn Louis Fletcher 43 2015 Independent Director
Kaj Blennow - 2018 Member of Medical Advisory Board
Lisa Ricciardi 64 2019 CEO, President & Director
Peggy Wallace 67 2016 Independent Director
John Harrison - 2018 Member of Medical Advisory Board
Larry Ereshefsky - - Member of Medical Advisory Board
Brett P. Monia 63 2020 Independent Director
Quang X. Pham 59 2023 Director
Henrik Zetterberg - 2018 Member of Medical Advisory Board
Rolf Craven - - Member of Scientific Advisory Board
Philip Scheltens - - Member of Medical Advisory Board
Ellen B. Richstone 72 2021 Independent Director
Mary Sano - - Member of Medical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CGTX Comments

Write your thoughts about Cognition Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email